Pfizer Inc. (PFE)
| Market Cap | 149.04B |
| Revenue (ttm) | 59.38B |
| Net Income (ttm) | 4.25B |
| Shares Out | 5.67B |
| EPS (ttm) | 0.74 |
| PE Ratio | 35.15 |
| Forward PE | 9.76 |
| Dividend | $1.72 (6.54%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 27,472,450 |
| Open | 26.40 |
| Previous Close | 26.49 |
| Day's Range | 26.22 - 26.56 |
| 52-Week Range | 24.48 - 31.54 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 32.17 (+22.32%) |
| Earnings Date | Feb 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $32.17, which is an increase of 22.32% from the latest price.
News
7 Stocks I'm Buying Amid This Goldilocks (For Now) Economy
There is an often overlooked difference between income investing and dividend growth investing. The two are not the same. Timely charts showing that inflation is even more subdued than the official CP...
Depo-Provera Contraceptive Manufacturer Pfizer Target of Consumer Lawsuit, Brain Tumors Linked to Use, According to Law Firm FeganScott
PITTSBURGH, Jan. 17, 2025 (GLOBE NEWSWIRE) -- A California woman has filed a class-action lawsuit claiming pharmaceutical giants Pfizer (PFE) and Viatris (VTRS), among others, manufactured and sold De...
3 Upcoming Dividend Increases
This week's anticipated dividend increases feature three companies with an average increase of 8.9% and a median increase of 8.7%. My strategy focuses on buying, holding, and adding companies that con...
What To Expect From PFE Stock In 2025?
Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly st...
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-...
Why Pfizer sold its $3 billion stake in Haleon
Pfizer's decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million share...
Pfizer Sells 700 Million Haleon Shares for $3 Billion
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge fu...
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. PFE Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.”
Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner
Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline
Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more.
Pfizer Inc. (PFE) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 12:45 PM ET Company Participants Albert Bourla - Chairman & Chief Executive Officer Conference Call Particip...
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Exeuctive Officer Albert Bourla said at the JPMorgan Healthcar...
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
The 'Dogs of the Dow' strategy can be applied to Pfizer in 2025 for its 6.4% dividend and a former 'Dog.'. PFE's growth recovery, historical cheap valuation, and positive investment sentiment make it ...
Pfizer's bladder cancer therapy meets main goal in late-stage study
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of certain complications, including cancer recurrence, the drugmaker said on Fr...
Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody...
Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills
Seven of the ten lowest-priced BBB Dogs, including Altria, Pfizer, and Verizon, are ready to buy, with dividends from $1K invested exceeding single share prices. Analysts project 16.27% to 32.98% net ...
There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.
UBS lowered its price targets for Pfizer, Merck, and Moderna stocks.
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tu...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at...
AUA Partners with Pfizer to Launch $1.5 Million RFP to Advance Care for Patients with Advanced Prostate Cancer
BALTIMORE, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The American Urological Association Education and Research, Inc. (AUAER) is proud to announce a collaboration with Pfizer Medical Grants & Partnerships (GM...
Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics
Collaboration will leverage Atavistik Bio's proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio has ra...